Rad in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection

Transplantation

Volumn 71, Issue 10, 2001, Pages 1400-1406

  Kahan, Barry D ^a   Kaplan, B ^b   Lorber, M I ^c   Winkler, M ^d   Cambon, N ^e   Boger, R S ^e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIMITOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MACROLIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCYTOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THROMBOCYTOPENIA;

EID: 0035958104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200105270-00008     Document Type: Article

References (15)

1. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
2. SDZ RAD, a new rapamycin derivative
3. A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients
4. Steady-state pharmacokinetics and tolerability of RAD and its influence on cyclosporine in stable renal transplant patients
5. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
7. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
9. The correlation of Banff scoring with reversibility of first and recurrent rejection episodes
10. Morphologic criteria of chronic renal allograft rejection
11. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
12. Chronic graft rejection
13. Immunosuppression enhances atherogenicity of lipid profile after transplantation
14. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates